ITI-1000の新興薬剤に関する洞察と市場予測：2032年

Immunomic Therapeutics (ITI) は、免疫賦活作用と抗悪性腫瘍作用が期待されるヒトサイトメガロウイルス（CMV）マトリックスタンパク質pp65をコードするmRNAを、短いリソソーム関連膜タンパク質（shLAMP）との融合タンパク質として担持した自己樹状細胞（DC）からなるがん細胞ワクチンであるITI-1000（pp65 DCワクチン）を開発しています。ワクチン接種の際、自家ワクチンは免疫系をCMV pp65ペプチドにさらし、CMV pp65発現腫瘍細胞に対する細胞傷害性Tリンパ球（CTL）反応を誘発する可能性があります。shLAMPの組み込みは、CMV pp-65抗原をリソソームコンパートメントに導き、その結果、MHCクラスII抗原提示が増強され、CD4陽性T細胞応答を促進する可能性があります。CMV pp65タンパク質は、CMVのエンベロープ型サブウイルス粒子の主要成分であり、ある種の腫瘍で発現しています。

ITI-1000は、新たにGBMと診断された患者を対象とした無作為化盲検プラセボ対照第II相試験で試験中であり、2022年までに終了する予定です。

今後数年間で、多形性膠芽腫（GBM）の市場シナリオは、世界中の広範な研究と医療支出の増加により変化します。各社は、病状を治療／改善するための新たなアプローチに焦点を当てた治療法を開発し、課題を評価し、ITI-1000の優位性に影響を与える可能性のある機会を模索しています。GBMに対する他の新興製品がITI-1000に厳しい市場競争を与えることが予想され、近い将来、後発の新興治療薬が上市されれば、市場に大きな影響を与えるとみられています。

当レポートでは、主要7ヶ国におけるITI-1000市場について調査し、市場の概要とともに、2026年～2032年の売上予測データ、競合情勢、および国別動向などを提供しています。

目次

第1章 レポートのイントロダクション

第2章 多形性膠芽腫（GBM）に対するITI-1000の概要

• 製品の詳細
• 臨床開発
  • 臨床研究
  • 臨床試験情報
  • 安全性と有効性
• その他の開発活動
• 製品概要

第3章 競合情勢（上市済み治療法）

第4章 競合情勢（後期段階の新興治療法）

第5章 ITI-1000市場評価

• GBMに対するITI-1000の市場見通し
• 主要7ヶ国市場分析
  • 主要7ヶ国におけるGBMに対するITI-1000の市場規模
• 国別市場分析
  • 米国
  • ドイツ
  • 英国

第6章 SWOT分析

第7章 アナリストの見解

第8章 付録

第9章 DelveInsightのサービス内容

第10章 免責事項

第11章 DelveInsightについて

第12章 レポート購入オプション

List of Tables

• Table 1: ITI-1000, Clinical Trial Description, 2023
• Table 2: ITI-1000, General Description
• Table 3: Competitive Landscape (Marketed Therapies)
• Table 4: Competitive Landscape (Emerging Therapies)
• Table 5: ITI-1000 Market Size in the 7MM, in USD million (2019-2032)
• Table 6: ITI-1000 Market Size in the US, in USD million (2019-2032)
• Table 7: ITI-1000 Market Size in Germany, in USD million (2019-2032)
• Table 8: ITI-1000 Market Size in France, in USD million (2019-2032)
• Table 9: ITI-1000 Market Size in Italy, in USD million (2019-2032)
• Table 10: ITI-1000 Market Size in Spain, in USD million (2019-2032)
• Table 11: ITI-1000 Market Size in the UK, in USD million (2019-2032)
• Table 12: ITI-1000 Market Size in Japan, in USD million (2019-2032)

List of Figures

• Figure 1: ITI-1000 Market Size in the 7MM, USD million (2019-2032)
• Figure 2: ITI-1000 Market Size in the United States, USD million (2019-2032)
• Figure 3: ITI-1000 Market Size in Germany, USD million (2019-2032)
• Figure 4: ITI-1000 Market Size in France, USD million (2019-2032)
• Figure 5: ITI-1000 Market Size in Italy, USD million (2019-2032)
• Figure 6: ITI-1000 Market Size in Spain, USD million (2019-2032)
• Figure 7: ITI-1000 Market Size in the United Kingdom, USD million (2019-2032)
• Figure 8: ITI-1000 Market Size in Japan, USD million (2019-2032)

“"ITI-1000 Emerging Drug Insight and Market Forecast - 2032" report provides comprehensive insights about ITI-1000 for glioblastoma multiforme (GBM) in the seven major markets. A detailed picture of the ITI-1000 for GBM in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the ITI-1000 for GBM. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the ITI-1000 market forecast analysis for GBM in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in GBM.

Drug Summary:

Immunomic Therapeutics (ITI) is developing ITI-1000 (pp65 DC vaccine), which is a cancer cell vaccine consisting of autologous dendritic cells (DCs) loaded with mRNA encoding the human cytomegalovirus (CMV) matrix protein pp65 as a fusion protein with the short lysosome-associated membrane protein (shLAMP), with potential immunostimulatory and antineoplastic activities. Upon vaccination, the autologous vaccine exposes the immune system to the CMV pp65 peptide, which may elicit a cytotoxic T-lymphocyte (CTL) response against CMV pp65-expressing tumor cells. The incorporation of shLAMP may route CMV pp-65 antigens into the lysosomal compartment, resulting in enhanced MHC Class II antigen presentation, thereby promoting CD4-positive T-cell responses. The CMV pp65 protein is the primary component of the enveloped sub-viral particle of CMV and is expressed in certain tumor types (National Cancer Institute, n.d.-a).

ITI-1000 is being tested in a randomized, blinded, and placebo-controlled Phase II study in patients with newly diagnosed GBM that is anticipated to close by 2022.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the ITI-1000 description, mechanism of action, dosage and administration, research and development activities in glioblastoma multiforme (GBM).
• Elaborated details on ITI-1000 regulatory milestones and other development activities have been provided in this report.
• The report also highlights the ITI-1000 research and development activities in GBM across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around ITI-1000.
• The report contains forecasted sales of ITI-1000 for GBM till 2032.
• Comprehensive coverage of the late-stage emerging therapies for GBM.
• The report also features the SWOT analysis with analyst views for ITI-1000 in GBM.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

ITI-1000 Analytical Perspective by DelveInsight

In-depth ITI-1000 Market Assessment

This report provides a detailed market assessment of ITI-1000 for glioblastoma multiforme (GBM) in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2026 to 2032.

ITI-1000 Clinical Assessment

The report provides the clinical trials information of ITI-1000 for GBM covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for glioblastoma multiforme (GBM) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence ITI-1000 dominance.
• Other emerging products for GBM are expected to give tough market competition to ITI-1000 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of ITI-1000 in GBM.
• Our in-depth analysis of the forecasted sales data of ITI-1000 from 2026 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the ITI-1000 in GBM.

Key Questions:

• What is the product type, route of administration and mechanism of action of ITI-1000?
• What is the clinical trial status of the study related to ITI-1000 in glioblastoma multiforme (GBM) and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the ITI-1000 development?
• What are the key designations that have been granted to ITI-1000 for GBM?
• What is the forecasted market scenario of ITI-1000 for GBM?
• What are the forecasted sales of ITI-1000 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to ITI-1000 for GBM?
• Which are the late-stage emerging therapies under development for the treatment of GBM?

Table of Contents

1. Report Introduction

2. ITI-1000 Overview in GBM

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. ITI-1000 Market Assessment

• 5.1. Market Outlook of ITI-1000 in GBM
• 5.2. 7MM Analysis
  • 5.2.1. Market Size of ITI-1000 in the 7MM for GBM
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of ITI-1000 in the United States for GBM
  • 5.3.2. Market Size of ITI-1000 in Germany for GBM
  • 5.3.3. Market Size of ITI-1000 in France for GBM
  • 5.3.4. Market Size of ITI-1000 in Italy for GBM
  • 5.3.5. Market Size of ITI-1000 in Spain for GBM
  • 5.3.6. Market Size of ITI-1000 in the United Kingdom for GBM
  • 5.3.7. Market Size of ITI-1000 in Japan for GBM

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options